Risk of Gastrointestinal Perforation in Patients With Rheumatic Diseases Exposed to Janus Kinase Inhibitors Versus Adalimumab: A Nationwide Cohort Study
Main finding · GIPResult — go to the resultWeighted hazard ratio 1.1 95% CI 0.7–1.9Authors' conclusion
In this nationwide cohort study, the rates of GIPs did not differ between groups of patients who received JAKi and adalimumab treatment.
Study context
- Population
- Patients with a rheumatic disease with first dispensation of JAK inhibitor (JAKi) or adalimumab, July 2017 to December 2021, French national health data system
- Participants
- 39,758 patients
- Exposure
- JAKi vs adalimumab
- Outcome
- Occurrence of gastrointestinal perforation (GIP)
- Follow-up
- End May 2022
Methodological detailsnationwide, population-based, inverse probability of treatment weighting
- Nationwide
- Population-based
- Inverse probability of treatment weighting
Main finding
GIP
Weighted hazard ratio
1.1
95% CI 0.7–1.9
P = 0.65
Events by group
JAKivs Adalimumab
wHR 1.1 (95% CI 0.7–1.9); P = 0.65
As reported in the abstract
Observational data: associations, not effects.
Further findings
Gastrointestinal perforation (GIP) by type of JAKi and by type of rheumatic disease (subgroups)
- Results consistent whatever the subgroup, despite lack of power in some subgroup analyses
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Risk of Gastrointestinal Perforation in Patients With Rheumatic Diseases Exposed to Janus Kinase Inhibitors Versus Adalimumab: A Nationwide Cohort Study. Arthritis Rheumatol. Published 30 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →